Company

Krystal Biotech, Inc.

Headquarters: Pittsburgh, PA, United States

Employees: 119

CEO: Mr. Krish S. Krishnan M.B.A., M.S.

NASDAQ: KRYS +8.35%

Market Cap

$4.13 Billion

USD as of July 1, 2025

Market Cap History

Krystal Biotech, Inc. market capitalization over time

Evolution of Krystal Biotech, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Krystal Biotech, Inc.

Detailed Description

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Financials

Last Financial Reports Date March 31, 2025
Revenue TTM $333.4 M
EBITDA $165.3 M
Gross Profit TTM $310.8 M
Profit Margin 37.18%
Operating Margin 41.03%
Quarterly Revenue Growth 94.90%
Financial Reports & Statistics

Stocks & Indices

Krystal Biotech, Inc. has the following listings and related stock indices.


Stock: NASDAQ: KRYS wb_incandescent

Stock: FSX: 4KB wb_incandescent

Stock: XSTU: 4KB wb_incandescent

Details

Headquarters:

2100 Wharton Street

Suite 701

Pittsburgh, PA 15203

United States

Phone: 412 586 5830